Raltegravir

Christin Kilcrease, Pharm.D.
Pediatric Dosing Author: Bethany Sharpless Chalk, Pharm.D., BCPPS
Raltegravir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced patients with evidence of HIV replication despite ongoing ART.
  • Treatment of HIV-1 infection in combination with other ARV agents in ART-naive patients.

NON-FDA APPROVED USES

  • HIV-1 nonoccupational postexposure prophylaxis (nPEP): 400 mg tablet twice daily for 28 days in combination with other antiretrovirals. Therapy should be initiated within 72 hours.
  • HIV-1 occupational postexposure prophylaxis (oPEP): 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Therapy should be initiated as soon as possible after occupational exposure.
  • Substitution for other ARV agents due to drug toxicity or intolerance in pts on a suppressive regimen

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of HIV-1 infection in combination with other ARV agents in ART-experienced patients with evidence of HIV replication despite ongoing ART.
  • Treatment of HIV-1 infection in combination with other ARV agents in ART-naive patients.

NON-FDA APPROVED USES

  • HIV-1 nonoccupational postexposure prophylaxis (nPEP): 400 mg tablet twice daily for 28 days in combination with other antiretrovirals. Therapy should be initiated within 72 hours.
  • HIV-1 occupational postexposure prophylaxis (oPEP): 400 mg twice daily for 4 weeks with concomitant emtricitabine/tenofovir. Therapy should be initiated as soon as possible after occupational exposure.
  • Substitution for other ARV agents due to drug toxicity or intolerance in pts on a suppressive regimen

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: February 12, 2022